Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab

Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.
Latest website image capture
Clouds background image

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page

  1. Check
    today
    Change Detected
    Summary
    The study's list of identifiers now includes '2016 ( U.S. NIH Grant/Contract )', adding NIH grant attribution to the record.
    Difference
    0.1%
    Check dated 2026-08-25T16:31:54.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    A new revision label v3.6.5 was added to the page and the previous label v3.6.4 was removed, signaling a small platform build update.
    Difference
    0.0%
    Check dated 2026-08-11T08:07:42.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    The page revision metadata was updated from v3.6.3 to v3.6.4, signaling a minor update to the record's metadata; no changes to the study content are indicated.
    Difference
    0.0%
    Check dated 2026-07-28T05:17:49.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.6.2 to v3.6.3, indicating a minor site update. No core content or study data on the page is affected by this change.
    Difference
    0.0%
    Check dated 2026-07-06T16:37:57.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.0 to v3.6.2 on the page, signaling a version update of the page rendering. This appears to be a backend/content-management-system update rather than a modification to the study data or user-facing content.
    Difference
    0.0%
    Check dated 2026-06-29T08:41:50.000Z thumbnail image
  8. Check
    71 days ago
    Change Detected
    Summary
    The page now adds sections that guide users (How to Read a Study Record, Common Questions, How to Join a Study) and explicitly states that recruitment has ended; it also updates the Revision line from v3.5.5 to v3.6.0 and adjusts the Intervention/Treatment heading formatting.
    Difference
    0.4%
    Check dated 2026-06-15T08:22:39.000Z thumbnail image

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab

Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.